Comparison of serologic assays for Middle East respiratory syndrome coronavirus

Ruth Harvey; Giada Mattiuzzo; Mark Hassall; Andrea Sieberg; Marcel A. Müller; Christian Drosten; Peter Rigsby; L. Caly; C. Li; L. Zhao; W. Tan; M. Peiris; M. Perera; C. Kang; J. S. Wang; B. Haagmans; N. M.A. Okba; R. Gopal; S. Myhill; N. Thornburg

doi:10.3201/eid2510.190497

Comparison of serologic assays for Middle East respiratory syndrome coronavirus

Ruth Harvey, Giada Mattiuzzo^*, Mark Hassall, Andrea Sieberg, Marcel A. Müller, Christian Drosten, Peter Rigsby, L. Caly, C. Li, L. Zhao, W. Tan, M. Peiris, M. Perera, C. Kang, J. S. Wang, B. Haagmans, N. M.A. Okba, R. Gopal, S. Myhill, N. Thornburg

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

Abstract

Middle East respiratory syndrome coronavirus (MERSCoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results.

Original language	English
Pages (from-to)	1878-1883
Number of pages	6
Journal	Emerging Infectious Diseases
Volume	25
Issue number	10
DOIs	https://doi.org/10.3201/eid2510.190497
Publication status	Published - 2019

Bibliographical note

Funding Information:
C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316).

Funding Information:
We thank the following institutions and organizations: Universit?tsklinikum, Bonn, Germany; Charit?-Universit?tsmedizin, Berlin, Germany; Korea National Institute of Health; the Central Public Health Laboratory, Ministry of Health, Sultanate of Oman; Public Health Department, Supreme Council of Health, Qatar; the Ministry of Health, Public Health Directorate, Kingdom of Saudi Arabia; SAb Biotherapeutics, South Dakota, USA. We also thank Humayun Asghar from the WHO Eastern Mediterranean Regional Office for assistance obtaining the serum for the study. C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316).

Publisher Copyright:
© 2019 Centers for Disease Control and Prevention (CDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid2510.190497

Cite this

Harvey, R., Mattiuzzo, G., Hassall, M., Sieberg, A., Müller, M. A., Drosten, C., Rigsby, P., Caly, L., Li, C., Zhao, L., Tan, W., Peiris, M., Perera, M., Kang, C., Wang, J. S., Haagmans, B., Okba, N. M. A., Gopal, R., Myhill, S., & Thornburg, N. (2019). Comparison of serologic assays for Middle East respiratory syndrome coronavirus. Emerging Infectious Diseases, 25(10), 1878-1883. https://doi.org/10.3201/eid2510.190497

@article{6526a662042a49e7921a3e08b316fc7c,

title = "Comparison of serologic assays for Middle East respiratory syndrome coronavirus",

abstract = "Middle East respiratory syndrome coronavirus (MERSCoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results.",

author = "Ruth Harvey and Giada Mattiuzzo and Mark Hassall and Andrea Sieberg and M{\"u}ller, {Marcel A.} and Christian Drosten and Peter Rigsby and L. Caly and C. Li and L. Zhao and W. Tan and M. Peiris and M. Perera and C. Kang and Wang, {J. S.} and B. Haagmans and Okba, {N. M.A.} and R. Gopal and S. Myhill and N. Thornburg",

note = "Funding Information: C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316). Funding Information: We thank the following institutions and organizations: Universit?tsklinikum, Bonn, Germany; Charit?-Universit?tsmedizin, Berlin, Germany; Korea National Institute of Health; the Central Public Health Laboratory, Ministry of Health, Sultanate of Oman; Public Health Department, Supreme Council of Health, Qatar; the Ministry of Health, Public Health Directorate, Kingdom of Saudi Arabia; SAb Biotherapeutics, South Dakota, USA. We also thank Humayun Asghar from the WHO Eastern Mediterranean Regional Office for assistance obtaining the serum for the study. C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316). Publisher Copyright: {\textcopyright} 2019 Centers for Disease Control and Prevention (CDC). All rights reserved.",

year = "2019",

doi = "10.3201/eid2510.190497",

language = "English",

volume = "25",

pages = "1878--1883",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "10",

}

Harvey, R, Mattiuzzo, G, Hassall, M, Sieberg, A, Müller, MA, Drosten, C, Rigsby, P, Caly, L, Li, C, Zhao, L, Tan, W, Peiris, M, Perera, M, Kang, C, Wang, JS, Haagmans, B, Okba, NMA, Gopal, R, Myhill, S & Thornburg, N 2019, 'Comparison of serologic assays for Middle East respiratory syndrome coronavirus', Emerging Infectious Diseases, vol. 25, no. 10, pp. 1878-1883. https://doi.org/10.3201/eid2510.190497

TY - JOUR

T1 - Comparison of serologic assays for Middle East respiratory syndrome coronavirus

AU - Harvey, Ruth

AU - Mattiuzzo, Giada

AU - Hassall, Mark

AU - Sieberg, Andrea

AU - Müller, Marcel A.

AU - Drosten, Christian

AU - Rigsby, Peter

AU - Caly, L.

AU - Li, C.

AU - Zhao, L.

AU - Tan, W.

AU - Peiris, M.

AU - Perera, M.

AU - Kang, C.

AU - Wang, J. S.

AU - Haagmans, B.

AU - Okba, N. M.A.

AU - Gopal, R.

AU - Myhill, S.

AU - Thornburg, N.

N1 - Funding Information: C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316). Funding Information: We thank the following institutions and organizations: Universit?tsklinikum, Bonn, Germany; Charit?-Universit?tsmedizin, Berlin, Germany; Korea National Institute of Health; the Central Public Health Laboratory, Ministry of Health, Sultanate of Oman; Public Health Department, Supreme Council of Health, Qatar; the Ministry of Health, Public Health Directorate, Kingdom of Saudi Arabia; SAb Biotherapeutics, South Dakota, USA. We also thank Humayun Asghar from the WHO Eastern Mediterranean Regional Office for assistance obtaining the serum for the study. C.D. was supported by the Federal Ministry of Education and Research (BMBF) grant RAPID (no. 01KI1723A) and the EU-Horizon 2020 grants COMPARE (no. 643476) and EVAg (no. 653316). Publisher Copyright: © 2019 Centers for Disease Control and Prevention (CDC). All rights reserved.

PY - 2019

Y1 - 2019

N2 - Middle East respiratory syndrome coronavirus (MERSCoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results.

AB - Middle East respiratory syndrome coronavirus (MERSCoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results.

UR - http://www.scopus.com/inward/record.url?scp=85072351240&partnerID=8YFLogxK

U2 - 10.3201/eid2510.190497

DO - 10.3201/eid2510.190497

M3 - Article

C2 - 31423969

AN - SCOPUS:85072351240

VL - 25

SP - 1878

EP - 1883

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 10

ER -

Comparison of serologic assays for Middle East respiratory syndrome coronavirus

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this